Patients with type 2 diabetes mellitus (T2DM) and symptomatic coronary artery disease (CAD) treated with metformin fare better with the addition of vildagliptin versus glimepiride, as the former is associated with better glycaemic control and lipid profile, according to a study.
Prediabetes contributes to faster functional decline and disability, irrespective of the future development of diabetes, a study suggests. This association is partly mediated by cardiovascular diseases.
While there may be no particular survival benefit to performing revascularization on top of medical therapy, the combination does seem to reduce the risk of poor outcomes, such as fatal myocardial infarction and unplanned revascularizations and stroke, recent meta-analysis reports.
Intermittent fasting (IF) appears to reduce cardiometabolic risk factors through the alteration of the gut microbial community and functional pathways in metabolic syndrome (MetS) patients, results of a recent study have shown.
Among people at risk of type 2 diabetes mellitus (T2DM), lowered insulin clearance may be an early indicator of vascular damage independently of other classical cardiovascular disease (CVD) risk factors, a recent study reports.
Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.